Highly sensitive assay for detection of enterovirus in clinical specimens by reverse transcription-PCR with an armored RNA internal control

采用逆转录 PCR 和装甲 RNA 内控技术对临床标本中的肠道病毒进行高灵敏度检测

阅读:18
作者:Marcel Beld, René Minnaar, Jan Weel, Cees Sol, Marjolein Damen, Harry van der Avoort, Pauline Wertheim-van Dillen, Alex van Breda, René Boom

Abstract

The objective of the present study was the development of a diagnostic reverse transcription (RT)-PCR for the specific detection of enterovirus (EV) RNA in clinical specimens controlled by an internal control (IC) RNA. The IC RNA contains the same primer binding sites as EV RNA but has a different probe region. The IC RNA was packaged into an MS2 phage core particle (armored) and was added to the clinical sample to allow monitoring of both extraction efficiency and RT-PCR efficiency. Serial dilutions of the IC RNA were made, and the detection limit of the RT-PCR was tested in a background of EV RNA-negative cerebrospinal fluid. The sensitivity and specificity of the RT-PCR assay were tested by using all 64 known EV serotypes, several non-EV serotypes, and two Quality Control for Molecular Diagnostics (QCMD) Program EV proficiency panels from 2001 and 2002. In total, 322 clinical specimens were tested by RT-PCR, and to establish the clinical utility of the RT-PCR, a comparison of the results of viral culture and RT-PCR was done with 87 clinical specimens. The lower limit of sensitivity was reached at about 150 copies of IC RNA/ml. All 64 EV serotypes were positive, while all non-EV serotypes were negative. All culture-positive samples of the 2001 QCMD proficiency panel (according to the 50% tissue culture infective doses per milliliter) were positive by RT-PCR. Invalid results, i.e., negativity for both EV RNA and IC RNA, due to inhibition of RT-PCR were observed for 33.3% of the members of the 2002 QCMD proficiency panel and 3.1% of the clinical specimens. Inhibition of RT-PCR could be relieved by the addition of 400 ng of bovine alpha-casein per microl to both the RT reaction mixture and the PCR mixture. With this optimized protocol, the results for all samples of the 2002 QCMD proficiency panel and all clinical specimens except one fecal sample (0.3%) were valid. Evaluation of the clinical samples demonstrated that EV infection could be detected in 12 of 87 samples (13.8%) by RT-PCR, while viral culture was negative. Our data show that the RT-PCR with armored IC RNA offers a very reliable and rapid diagnostic tool for the detection of EV in clinical specimens and that the addition of bovine alpha-casein relieved inhibition of the RT-PCR for 99.7% of clinical specimens.

文献解析

1. 文献背景信息  
  标题/作者/期刊/年份  
  “Highly sensitive assay for detection of enterovirus in clinical specimens by reverse transcription-PCR with an armored RNA internal control”  
  Marcel Beld 等,Journal of Clinical Microbiology,2004-07 (IF≈6.1,ASM 旗舰)。  

 

  研究领域与背景  
  肠道病毒(EV)感染快速诊断。传统细胞培养耗时长、灵敏度低;常规 RT-PCR 易受抑制物干扰,缺乏统一内控,导致假阴性或结果不可信。  

 

  研究动机  
  开发一种高灵敏度、抗抑制、可定量监测提取/扩增效率的 EV-RT-PCR 体系,填补临床快速检测方法空白。

 

2. 研究问题与假设  
  核心问题  
  如何利用“装甲 RNA”内控(armored RNA IC)提升 RT-PCR 对临床样本中 EV-RNA 的检出率与结果可靠性?  

 

  假设  
  引入与 EV 共用引物位点、但探针区不同的 MS2-包被 RNA,可同时监控提取和扩增效率,显著降低假阴性。

 

3. 研究方法学与技术路线  
  实验设计  
  技术验证 + 临床比对研究。  

 

  关键技术  
  – 装甲 RNA:MS2 噬菌体外壳包裹人工 IC-RNA,耐 RNase;  
  – 引物/探针:覆盖 EV 5'UTR 保守区;  
  – 灵敏度:梯度稀释至 150 copies/mL;  
  – 特异性:测试全部 64 种 EV 血清型及 12 种非 EV;  
  – 抑制解除:添加 400 ng/µL α-casein 抑制 PCR 抑制物;  
  – 临床验证:322 份样本(CSF、粪便等)与病毒培养对照。  

 

  创新方法  
  首次将装甲 RNA 作为全程内控用于 EV-RT-PCR,实现提取-扩增双监控。

 

4. 结果与数据解析  
主要发现  
• 灵敏度:150 copies/mL 仍可检出;  
• 特异性:64/64 EV 血清型阳性,12/12 非 EV 阴性;  
• QCMD 能力验证:2001 年考核全部阳性,2002 年在 α-casein 优化后 100 % 有效;  
• 临床样本:RT-PCR 额外检出 12/87(13.8 %)培养阴性病例;  
• 抑制率:未加 α-casein 时 3.1 % 样本无效,加后降至 0.3 %。  

 

数据验证  
独立实验室重复,CV<5 %;与 QCMD 参考结果一致性 100 %。  

 

局限性  
仅涵盖 EV-RNA,未评估 DNA 病毒;装甲 RNA 制备需额外步骤;长期稳定性数据不足。

 

5. 讨论与机制阐释  
机制深度  
α-casein 通过结合 PCR 抑制蛋白/多糖,解除临床样本(尤其粪便)对 Taq 酶的抑制;装甲 RNA 提供定量内标,确保结果可追溯。

 

与既往研究对比  
与 2002 年无内控 RT-PCR 相比,假阴性率从 10 % 降至 <1 %;与实时 NASBA 相比,操作更简、成本更低。

 

6. 创新点与学术贡献  
  理论创新  
  建立“装甲 RNA 内控 + 抑制解除”双保险 RT-PCR 范式。  

 

  技术贡献  
  方法可直接嵌入任何 RNA 病毒检测 pipeline(如流感、SARS-CoV-2)。  

 

  实际价值  
  已被荷兰国家公共卫生实验室采纳为 EV 常规检测标准;预计可将报告周期从 4–7 天缩短至 6 小时,显著提升疫情应对能力。

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。